



Correlation of serum magnesium with serum levels of 25-hydroxyvitamin D in hemodialysis patients

Hamid Nasri*

Abstract

To find the association of serum magnesium levels, with serum 25-hydroxyvitamin D levels, in patients on regular hemodialysis, we conducted a study on 41 stable hemodialysis patients. We found a significant positive correlation of serum magnesium with 25-OH vitamin D ($r=0.40$ $p=0.009$). While magnesium deficiency increases serum fibroblast growth factor 23 concentration. Thus, the positive association of magnesium deficiency and fibroblast growth factor 23, further indicate the significance of magnesium and vitamin D deficiency, especially in hemodialysis patients.

Keywords: Hemodialysis, Magnesium, 25-Hydroxyvitamin D

Please cite this paper as: Nasri H. Correlation of serum magnesium with serum levels of 25-hydroxyvitamin D in hemodialysis patients. *J Parathyroid Dis* 2014; 2(1): 13-15.

Copyright © 2014 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

25-hydroxyvitamin D (25-OH vitamin D) is the main circulating metabolite of vitamin D (1). While the biological active form of vitamin D is 1,25(OH)₂ vitamin D, synthesized in the kidney, it is broadly accepted that the measurement of circulating 25(OH) vitamin D offers better evidence with respect to the patients' vitamin D status (1,2). Recently, various studies have shown the role of plasma 25(OH) vitamin D levels in mineral metabolism dysregulation in chronic renal failure. It has been found that a moderate reduction in plasma 25(OH) vitamin D levels plays a role in the development of secondary hyperparathyroidism in patients on hemodialysis, while a greater reduction in plasma 25(OH) vitamin D levels is related to osteomalacia and with the risk of emerging osteoporosis. It has been also found that, plasma 25(OH) vitamin D deficiency has been associated with adverse cardiovascular outcomes in epidemiologic studies. Magnesium is the dominant intracellular cation (1-3). Magnesium acts as a catalyst or activator for various intracellular enzymatic reactions, predominantly those which depend upon ATP, and the magnesium-ATP complex is a key intermediate substrate (4-8). Hypomagnesemia has been associated with cardiovascular risk factors and increased co-morbidity including hypertension, dyslipidemia and atherosclerosis. Various epidemiological investigations and clinical trials have

detected an inverse association between blood pressure and serum magnesium (9-12). Also, hypomagnesemia aggravates both atrial and ventricular arrhythmias (9-12). Changes in serum magnesium may influence some clinical features of patients on hemodialysis (4-12). While, renal excretion is the main route of elimination of magnesium from the body, a positive magnesium balance would be found in patients with kidney failure. However, the magnesium balance may be normal or even decreased in hemodialysis patients. This is possibly due to decreased dietary intake associated with worsened intestinal absorption. Impaired absorption of magnesium appears to be related to deficient synthesis of the active metabolite of vitamin D by the nonfunctioning kidneys (12-17). This study, therefore aimed to find the association of serum magnesium levels, with 25-hydroxyvitamin D levels, in patients on regular hemodialysis.

Patients and Methods

Patients

This is a cross-sectional study conducted in the hemodialysis section of Shahrekord University of Medical Sciences in Shahrekord, Iran. Patients with any active or chronic infection were excluded from the investigation.

Laboratory methods

The serum magnesium, calcium and phosphorus levels

Received: 24 November 2013, Accepted: 6 December 2013, ePublished: 1 March 2014

Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.

*Corresponding author: Prof. Hamid Nasri, E-mail: hamidnasri@med.mui.ac.ir

■ Implication for health policy/practice/research/medical education

To find the association of serum magnesium levels, with serum 25-hydroxyvitamin D, in patients on regular hemodialysis, we conducted a study on 41 stable hemodialysis patients. We found a significant positive correlation of serum magnesium with 25-OH vitamin D. While magnesium deficiency increases serum fibroblast growth factor 23 concentration. Thus, the positive association of magnesium deficiency and fibroblast growth factor 23, further indicate the significance of magnesium and vitamin D deficiency, especially in hemodialysis patients.

were measured using standard kits. Serum 25-OH vitamin D levels was assessed by the ELISA method using DRG kits of Germany (normal range, 25 to 125 nmol/L). The efficiency of hemodialysis was assessed by calculating the urea reduction rate (URR).

Ethical issues

1) The research followed the tenets of the Declaration of Helsinki; 2) informed consent was obtained; 3) the research was approved by the institutional review board.

Statistical analysis

For statistical analysis, descriptive data are expressed as mean (SD). Comparison between the groups was conducted using a Student's *t*-test. Statistical correlations were assessed using a partial correlation test. Statistical analysis was performed separately on females, males, diabetics, and non-diabetic individuals. All statistical analysis were performed using SPSS 11.5 (SPSS Inc., Chicago, IL, USA). Statistical significance was fixed at a $p < 0.05$.

Results

The total patients were 41 (males= 26, females= 15). Of them, there were 29 non-diabetic and 12 diabetic patients. The mean (SD) age of the study patients was 46 (17.6) years. The length of hemodialysis was 29.5 (34.7) months. The mean of serum magnesium and serum 25-OHvitamin D were 2.48 (0.41) mg/dl, and 7.6 (9.45) nmol/l, respectively. No significant difference was seen in the levels of serum magnesium, calcium, phosphorus, alkaline phosphatase and 25-hydroxyvitamin D between diabetics and non-diabetics ($p > 0.05$). No significant differences of serum magnesium, calcium, phosphorus, alkaline phosphatase and serum 25-hydroxyvitamin D were existed between males and females ($p > 0.05$). A significant positive correlation of serum magnesium and 25-OH vitamin D ($r = 0.40$ $p = 0.009$) was seen. This correlation was strongly positive in non-diabetic, diabetic,

female, and male groups individually.

Discussion

In this study, we found the significant positive correlation of serum magnesium with serum 25-hydroxyvitamin D levels in study patients. This correlation was strongly positive in non-diabetic, diabetic, female, and male groups studied population. To test the relationship of serum magnesium and vitamin D levels in 330 students, Kelishadi *et al.*, detected the significant positive association of magnesium with 25(OH) D serum level (18). Likewise, Gandhe *et al.*, conducted a study to examine the possible association of vitamin D3, and magnesium in type II diabetes mellitus patients. They noticed to a positive correlation of vitamin D with serum magnesium levels. They interpreted that, vitamin D levels can also affects the magnesium status (19). Fibroblast growth factor-23 is linked to the atherosclerosis and cardiovascular mortality in hemodialysis patients and healthy subjects (20,21). It was found that, magnesium deficiency increases serum fibroblast growth factor 23 (FGF23) levels too (20,21). Thus the positive association of magnesium deficiency and fibroblast growth factor 23 (20,21), further indicate the significance of magnesium and vitamin D deficiency, especially in hemodialysis patients.

Conclusion

There was a significant positive correlation of serum magnesium with serum 25-OH Vitamin D levels in hemodialysis patients. Magnesium deficiency increases serum fibroblast growth factor 23 concentration. Thus the positive association of magnesium deficiency and fibroblast growth factor 23, further indicate the significance of magnesium and vitamin D deficiency, especially in hemodialysis patients.

Author's contribution

HN is the single author of the manuscript.

Conflict of interests

The author declared no competing interests.

Ethical considerations

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the author.

Funding/Support

None.

References

1. Nasri H, Baradaran A. The association of 25-hydroxyvitamin D levels with secondary hyperparathyroidism in end-stage renal failure

- patients undergoing regular hemodialysis. *Arch Med Sci* 2005; 4: 236-40.
2. Walker JP, Hiramoto JS, Gasper WJ, Auyang P, Conte MS, Rapp JH, *et al.* Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end-stage renal disease. *J Vasc Surg* 2014; forthcoming.
 3. Descombes E, Fellay B, Hemett OM, Magnin JL, Fellay G. Oral postdialysischolecalciferol supplementation in patients on maintenance hemodialysis: a dose-response approach. *Int J Nephrol* 2014; 2014: 597429.
 4. Courivaud C, Davenport A. Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: agent provocateur or innocent bystander? *Kidney Int* 2014; 85(1): 17-20.
 5. Liu F, Zhang X, Qi H, Wang J, Wang M, Zhang Y, *et al.* Correlation of serum magnesium with cardiovascular risk factors in maintenance hemodialysis patients--a cross-sectional study. *Magnes Res* 2013; 26(3): 100-8.
 6. Nasri H. Re: association between serum magnesium and risk factors of cardiovascular disease in hemodialysis patients. *Iran J Kidney Dis* 2013;7(3): 241-2.
 7. Khatami MR, Mirchi E, Khazaeipour Z, Abdollahi A, Jahanmardi A. Association between serum magnesium and risk factors of cardiovascular disease in hemodialysis patients. *Iran J Kidney Dis* 2013; 7(1): 47-52.
 8. Nassiri AA, Hakemi MS. Serum magnesium level and cardiovascular disease in dialysis patients. *Iran J Kidney Dis* 2013; 7(1): 2-4.
 9. Houillier P. Mechanisms and regulation of renal magnesium transport. *Annu Rev Physiol* 2014; 76: 411-30.
 10. Sontia B, Touyz RM. Role of magnesium in hypertension. *Arch Biochem Biophys* 2007; 458: 33-9.
 11. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, *et al.* Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. *Am J Clin Nutr* 2013; 98: 160-173.
 12. Maier JA. Endothelial cells and magnesium: implications in atherosclerosis. *Clin Sci (Lond)* 2012; 122: 397-407.
 13. Rosanoff A, Seelig MS. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. *J Am Coll Nutr* 2004; 23: 501S-5S.
 14. Baradaran A, Nasri H. Correlation of serum magnesium with serum parathormone levels in patients on regular hemodialysis. *Saudi J Kidney Dis Transpl* 2006; 17(3): 344-50.
 15. Nasri H, Baradaran A. Correlation of serum magnesium with dyslipidemia in maintenance hemodialysis patients. *Acta Medica (Hradec Kralove)* 2004; 47(4): 263-5.
 16. Nasri H, Rafieian-Kopaei M. Significant difference of serum 25-hydroxyvitamin D level in male hemodialysis patients with our without diabetes; a single center study. *J Nephropharmacol* 2012; 1(2): 3-4.
 17. Ghorbani A, Baradaran A. Magnesium and diabetes mellitus. *J Ren InjPrev* 2012; 1(2): 46-47.
 18. Kelishadi R, Ataei E, Ardalan G, Nazemian M, Tajadini M, Heshmat R, *et al.* Relationship of Serum Magnesium and Vitamin D Levels in a Nationally-Representative Sample of Iranian Adolescents: The CASPIAN-III Study. *Int J Prev Med* 2014; 5(1): 99-103.
 19. Gandhe MB, Jain K, Gandhe SM. Evaluation of 25(OH) Vitamin D3 with Reference to Magnesium Status and Insulin Resistance in T2DM. *J Clin Diagn Res* 2013; 7(11): 2438-41.
 20. Asicioglu E, Kahveci A, Arikan H, Koc M, Tuglular S, Ozener C. Fibroblast growth factor-23 levels are associated with uric Acid but not carotid intima media thickness in renal transplant recipients. *Transplant Proc* 2014; 46(1): 180-3.
 21. Sany D, Elsayy AE, Aziz A, Elshahawy Y, Ahmed H, Aref H, *et al.* The value of serum FGF-23 as a cardiovascular marker in HD patients. *Saudi J Kidney Dis Transpl* 2014; 25(1): 44-52.